SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston.
Details of the presentation are as follows:
| Presentation Title: | Empowering Peptide Self Administration with Needle-Free Smart Capsules |
| Track: | Pioneering Devices to Increase the Reach of Peptide APIs |
| Date & Time: | Wednesday, June 19, 2024 from 2:15 to 2:45 PM Eastern time |
| Presenting Author: | Sharat Singh, PhD, Head of Research, Biora Therapeutics, Inc. |
Dr. Singh will also participate in a panel discussion on June 19 at 8:45 AM titled “Uncovering Innovations in Peptide Drug Delivery & Formulation for Improved Bioavailability,” alongside representatives from Eli Lilly, Merck, and Novo Nordisk.
Selections from the presentation will be made available on the Biora Therapeutics website following the event.
About Sharat Singh, PhD
Sharat Singh brings over 25 years of experience as a dynamic and innovative scientific leader to his role at Biora Therapeutics, where he is focused on development of the company’s ingestible drug-device combination product candidates. Dr. Singh previously held scientific leadership roles at Aclara Biosciences, Prometheus Laboratories, and Nestle Health Sciences, where he established partnerships with leading biotech/pharmaceutical companies and conducted multiple phase I/II clinical trials in both oncology and gastrointestinal disease. As Chief Scientific Officer at Prometheus Laboratories, Sharat worked on topical formulation of budesonide for both Crohn’s disease (marketed as Endocort) and ulcerative colitis. He is the key inventor of multiple platform technologies (CEER, ANSER, eTag, and LOCI) and has authored over 100 patents. In his academic career, Sharat conducted inter-disciplinary research as a postdoctoral fellow at Columbia University. He holds a PhD in Chemistry from IISc, Bangalore, and has authored over 100 manuscripts and presentations.
About the BioJet™ Systemic Oral Delivery Platform
Biora's BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases.
The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver a drug directly into the small intestine for uptake into systemic circulation. The BioJet device is approximately the size of a multivitamin and is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation at multi-milligram doses, without requiring complex reformulation.
Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 12 issued patents and 31 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs.
About Biora Therapeutics
Biora Therapeutics is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives.
Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “anticipate,” “forward,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390
Media Contact
media@bioratherapeutics.com
